1.3 0.03 (2.36%) | 10-10 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 1.56 | 1-year : | 1.82 |
Resists | First : | 1.34 | Second : | 1.56 |
Pivot price | 0 | |||
Supports | First : | 1.29 | Second : | 1.25 |
MAs | MA(5) : | 0 | MA(20) : | 0 |
MA(100) : | 0 | MA(250) : | 0 | |
MACD | MACD : | 0 | Signal : | 0 |
%K %D | K(14,3) : | 0 | D(3) : | 0 |
RSI | RSI(14): 0 | |||
52-week | High : | 1.34 | Low : | 1.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ZYNE ] has closed Bollinger Bands are 0% narrower than normal.
If tomorrow: | Open lower | Open higher |
High: | - | - |
Low: | - | - |
Close: | - | - |
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.
Wed, 11 Oct 2023
HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE - PR Newswire
Wed, 11 Oct 2023
Harmony Biosciences (HRMY) Competes Acquisition of Zynerba Pharmaceuticals - StreetInsider.com
Fri, 29 Sep 2023
Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday ... - Yahoo Finance
Fri, 15 Sep 2023
Insider Sell: President Terri Sebree Sells 12401 Shares of Zynerba Pharmaceuticals Inc - GuruFocus.com
Mon, 14 Aug 2023
Harmony Biosciences Buys Zynerba Pharmaceuticals in $60M Deal - Green Market Report
Mon, 14 Aug 2023
Zynerba Pharma stock rockets on premium priced Harmony deal - Proactive Investors USA
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Drug Manufacturers—Specialty & Generic
|
|
Shares Out | 0 (M) |
Shares Float | 0 (M) |
Held by Insiders | 0 (%) |
Held by Institutions | 0 (%) |
Shares Short | 0 (K) |
Shares Short P.Month | 0 (K) |
EPS | 0 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | 0 % |
Return on Equity (ttm) | 0 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | 0 (M) |
PE Ratio | 0 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | 0 |
Price to Cash Flow | 0 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |